Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Phastar Names Graham Clark CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Phastar Names Graham Clark CEO

Clark brings 25 years of experience in life sciences, financial, and professional services organizations.

By: Anthony Vecchione

Phastar, a global specialist biometrics CRO, appointed Graham Clark Chief Executive Officer. Clark will succeed Andrew MacGarvey, who will become chief operating officer and maintain his board position.

As former managing director with Phlexglobal, a global authority in Trial Master File (TMF) technology and services, Clark adds strong operational and commercial experience to the Phastar team. An accomplished leader with a proven track record in operations, strategy, and change management, he brings over 25 years’ experience in life sciences, financial, and professional services organizations.

Board chair Steve Kent, said, “We are very pleased to welcome Graham to Phastar. Graham is known for building strong teams around a compelling vision, providing clear focus and results orientation, and managing teams through transformational change. We are confident that Graham is very well-placed to take Phastar to the next level as global specialist biometrics CRO and further enhance the value we deliver to our customers, employees, and life sciences industry as a whole.”

Clark said, “I am delighted with my appointment to lead Phastar, cementing our position as a world-leading, specialist biometric CRO. I believe we are uniquely placed to unlock the value of increasingly complex data and accelerate the development of promising new medicines. Phastar has enjoyed unprecedented growth underpinned by quality service and first-class delivery, earning its reputation of excellence within biopharma and medical device communities. I am looking forward to working with our talented team to continue delivering the highest quality data standards. These are exciting times to join Phastar and build on a shared legacy, and I’m excited to spearhead this new wave of growth.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics